Join
Live feed
·
INSIDERFilingvia Quantisnow
C4 Therapeutics Inc. logo

Director Anderson Kenneth Carl was granted 2,650 shares, increasing direct ownership by 4% to 71,950 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CCCC· C4 Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CCCC (C4 Therapeutics Inc.) and more on Quantisnow.